Mangoceuticals granted Nasdaq bid-price extension
Mangoceuticals, Inc. reported that Nasdaq has granted an additional 180-calendar-day extension, until February 1, 2027, for the company to regain compliance with the Nasdaq Capital Market minimum bid price requirement of $1.00 per share.
Rhea-AI Filing Summary
Mangoceuticals, Inc. reported that Nasdaq has granted an additional 180-calendar-day extension, until February 1, 2027, for the company to regain compliance with the Nasdaq Capital Market minimum bid price requirement of $1.00 per share.
The extension was granted because the company meets all other initial listing standards and has indicated it may use a reverse stock split, if needed. The notice does not currently affect trading of the common stock. Mangoceuticals also highlighted its definitive business combination agreement with Nuclea Energy Inc., which is developing the Morpheus microreactor, and described its existing MangoRx men’s health telemedicine business.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Additional compliance period: 180 calendar days
New compliance deadline: February 1, 2027
Minimum bid price: $1.00 per share
+3 more
6 metrics
Additional compliance period
180 calendar days
Length of Nasdaq Second Compliance Period to regain bid price compliance
New compliance deadline
February 1, 2027
End of Second Compliance Period for Nasdaq minimum bid price rule
Minimum bid price
$1.00 per share
Required closing bid price under Nasdaq Listing Rule 5550(a)(2)
Compliance trading window
10 consecutive business days
Duration shares must meet or exceed $1.00 bid price
Initial compliance deadline
August 3, 2026
End of the first 180-day period to regain bid price compliance
Initial deficiency notice date
February 4, 2026
Date Nasdaq first notified Mangoceuticals of bid price deficiency
Key Terms
Nasdaq Listing Rule 5550(a)(2), reverse stock split, business combination agreement, Morpheus microreactor, +1 more
5 terms
Nasdaq Listing Rule 5550(a)(2) regulatory
"to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2)"
reverse stock split financial
"intention to cure the deficiency within the extension period, if necessary, through a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
business combination agreement financial
"continues to advance its previously announced definitive business combination agreement with Nuclea Energy Inc."
A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.
Morpheus microreactor technical
"Nuclea Energy Inc., an advanced nuclear technology company developing the Morpheus microreactor"
proxy statement regulatory
"including a registration statement containing a proxy statement in connection with the stockholder approval"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq extension did Mangoceuticals (MGRX) receive on its bid price requirement?
Nasdaq granted Mangoceuticals an additional 180-calendar-day extension to regain compliance with its minimum bid price rule. The company now has until February 1, 2027, to restore a closing bid of at least $1.00 per share for 10 consecutive business days.
What is the minimum bid price Mangoceuticals (MGRX) must meet to comply with Nasdaq rules?
Mangoceuticals must achieve and maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. Meeting this threshold by February 1, 2027 is required to satisfy Nasdaq Listing Rule 5550(a)(2).
How does Mangoceuticals (MGRX) plan to regain Nasdaq bid price compliance?
Mangoceuticals informed Nasdaq it intends to cure the deficiency and may effect a reverse stock split within the extension period. The company plans to closely monitor its share price and take all necessary actions to regain compliance with listing standards.
Does the Nasdaq Second Notice impact current trading of Mangoceuticals (MGRX) stock?
The Second Notice from Nasdaq has no effect on the current listing or trading of Mangoceuticals’ common stock. Shares continue to trade on the Nasdaq Capital Market while the company works toward restoring compliance with the minimum bid price requirement.
What business combination is Mangoceuticals (MGRX) pursuing with Nuclea Energy?
Mangoceuticals is advancing a definitive business combination agreement with Nuclea Energy Inc., an advanced nuclear technology company. Nuclea is developing the Morpheus microreactor, aimed at providing carbon-free power for AI infrastructure, data centers, and other applications.
What is Mangoceuticals’ (MGRX) current core business outside the Nuclea Energy deal?
Mangoceuticals, through its MangoRx platform, focuses on men’s health and wellness via telemedicine. It offers pharmaceutical-based products for erectile dysfunction, hair growth, hormone replacement therapies, and weight management, with prescriptions reviewed by licensed providers and filled by a partner pharmacy.
AI-generated analysis. How Rhea-AI works. Not financial advice.
